… biosimilars company and subsidiary of Biocon Ltd, has launched Nepexto®, … diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and … the biosimilars business globally, Biocon Biologics is building on the …

Bengaluru: Biocon’s biosimilars arm Biocon Biologics announced the launch of … diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and … brand in other markets soon. “Biocon Biologics is building on the …

… diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and … of the biosimilars business globally, Biocon Biologics is building on the … offering, it said. Shares of Biocon were trading 1.72 per …

… the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, … biosimilars business in 2022, Biocon Biologics has been strategically expanding … New Co Limited, a Biocon Biologics company. Aditya Bhagchandani …

… and renewed retail interest.  Biocon shares rose 2% on … these two pharma counters:  Biocon Biocon Biologics, its arm, secured … ‘bearish’ last week. Biocon sentiment and message volume on … associated with conditions such as arthritis, ankylosing spondylitis, and …

… The denosumab biosimilars mark Biocon’s third and fourth … adults with active psoriatic arthritis or moderately to … 5). References 1. Biocon Biologics. Biocon Biologics Receives MHRA UK … 7, 2025. 5. Biocon Biologics. Biocon Biologics Receives MHRA Approval …

… biosimilar acceptance in treating psoriasis, arthritis, and Crohn’s disease. … reference biologic. References 1. Biocon Biologics. Biocon Biologics Receives MHRA Approval … Feb. 18, 2025. 5. Biocon Biologics. Biocon Biologics Completes Acquisition of Viatris …

… biosimilars company and subsidiary of Biocon, has announced that the Medicines … , and adults with active psoriatic arthritis or moderately to severely active …

… biosimilars company and subsidiary of Biocon received the approval from the … , and adults with active psoriatic arthritis or moderately to severely active …

… , the biosimilars arm of Biocon has received marketing approval from … , and adults with active psoriatic arthritis or moderately to severely active …